Nearly five decades have passed since the onset of the HIV epidemic, yet it remains a critical public health challenge, with over a million individuals globally contracting the virus each year. The United States has set an ambitious goal to eliminate HIV by 2030, focusing on preventing new infections and addressing disparities in health equity. This endeavor faces numerous challenges, but leaders in the field, like Dr. Tomas Cihlar, Senior Vice President of Virology at Gilead, are at the forefront of innovation.
Dr. Cihlar has dedicated over 30 years to combating viral infections, including HIV, hepatitis, and COVID-19. His most notable contribution is the development of lenacapavir, a groundbreaking treatment that offers both prevention and therapy for HIV through biannual injections. "Our journey began with a vision to disrupt the virus's lifecycle based on pioneering research from the University of Utah," he shares. "Our aim was to inhibit the virus's ability to infect and replicate."
Lenacapavir, a molecule developed over two decades, targets critical phases of the HIV replication process, particularly the viral capsid--a protective shell that encases the virus's genetic material. After receiving FDA approval in 2025, lenacapavir became part of a new class of HIV prevention methods known as pre-exposure prophylaxis (PrEP), available to high-risk individuals.
In an exclusive interview with Men's Health, Dr. Cihlar discussed the significance of lenacapavir, its development process, and the hopeful prospects for a once-yearly PrEP option. The initial phases of lenacapavir's testing involved careful monitoring for safety and efficacy, leading to its approval for patients with multi-drug resistant HIV. Subsequent studies expanded its use to a broader population, culminating in its approval in multiple regions under the brand names Sunlenca and Yeztugo.
Dr. Cihlar emphasized the potential of lenacapavir to revolutionize HIV prevention, particularly in vulnerable populations. "The ease of administration could significantly enhance protection in areas severely affected by HIV," he noted. "If we can provide a solution that requires minimal compliance, we could not only curb the epidemic but potentially eliminate it."
Looking ahead, Gilead is exploring a once-a-year formulation of lenacapavir, which could further simplify treatment and prevention. "The goal is to make HIV protection as straightforward as possible, allowing individuals to focus on their lives without the constant worry of daily medication," Dr. Cihlar explained.
As the fight against HIV continues, the collaborative efforts of organizations and researchers are crucial. Gilead's commitment to equitable access through partnerships with global health organizations aims to ensure that effective treatments reach those who need them most. "Our vision is clear: to see a substantial decline in new HIV infections globally," Dr. Cihlar stated. "With continued innovation and accessibility, we can make significant strides towards ending the HIV epidemic."
As we progress into the future, advancements like lenacapavir may not only transform the landscape of HIV prevention and treatment but also inspire a new era of hope in global health initiatives.
